Chelsie Derman

A study found depressive symptoms in older individuals with normal cognition were linked to amyloid pathology in APOE ε4 noncarriers but not carriers.

A new study showed sedative, hypnotic, and anxiolytic use disorder diagnoses rose 3- to 5-fold from 2001–2019 among adolescents and young adults.

A new study identified psychiatric, neurological, and somatic comorbidities of intermittent explosive disorder.

HCPLive spoke with Mattingly about esketamine’s recent FDA approval as a monotherapy for treatment-resistant depression which works within hours or 1 – 2 days.

Dupilumab improves severe CRSwNP symptoms, such as nasal obstruction and quality of life, showing significant efficacy within 6-12 months.

Mindfulness eased opioid cravings in OUD patients on buprenorphine but showed no added benefit over recovery support for abstinence, substance use, or anxiety.

The FDA approved esketamine (SPRAVATO) nasal spray as the first monotherapy for adults with TRD, showing rapid efficacy at 4 weeks.

A study showed that vitamins, supplements, and antipsychotics were associated with an increased dementia risk.

A new study found high concentrations of pollen from 3 species classes—ragweed, deciduous trees, and grass—are linked to increased chronic respiratory mortality.

A new study shows that employee stress improves when using a mindfulness meditation app for under or above 5 minutes (the more effective option).

Despite the surge in telemental health use in patients with schizophrenia, fewer people in racial or ethnic minority groups had a telemental health visit compared to White people.

Boehringer Ingelheim’s phase 3 trial of iclepertin for cognitive impairment in schizophrenia failed to meet primary and secondary endpoints, showing no significant effects.

A study shows the causal link between apoA-I and chronic obstructive pulmonary disease, showing lipid metabolism's role in the pathogenesis of COPD.

A new study showed ADHD incidence trends fluctuated between 2016-2023, with adult diagnoses rising post-COVID-19 and adolescent rates remaining stable after an initial decline.

Anti-CGRP monoclonal antibodies for migraine prevention were not linked to increased cardiovascular risk, per a Medicare study, addressing earlier safety concerns.

2 phase 3 trials show iptacopan improves fatigue, quality of life, and hematologic markers in C5i-experienced or -naive patients with paroxysmal nocturnal hemoglobinuria.

A study showed age and sex perform better at identifying the risk for opioid use disorder than candidate genetic variants.

Subjective poor sleep quality is tied to greater systolic blood pressure in adults ≤ 49 years with optimal sleep duration, compared with adults ≥ 50 years.

A study found many people with dementia live approximately 1 third of their remaining life expectancy in nursing homes.

In a recent study, participants reported worse patient care experience and staff responsiveness following the private equity acquisition of hospitals.

HCPLive spoke with John M. Kane, MD, about phase 2 LB-102 data for schizophrenia.

A new study found that depression prevalence among older adults was greater for those who were 65 – 69 years old.

SP-624, a SIRT6 activator, showed promise in an exploratory study for treating depression and cognition in females with MDD. Positive EEG data suggests enhanced neural connectivity.

New research reveals that frequent social media use, especially active use of platforms such as TikTok and Facebook, is linked to greater irritability levels.

A recent study showed expression profiles of amacrine cells, the interneurons within the retina, were enriched in schizophrenia genetic risk factors.

Individuals with stable schizophrenia struggle to recognize facial emotions such as sadness, disgust, and anger—but not happiness—which may impact social interactions.

A study found long-acting injectables reduced mean Young Mania Rating Scales scores in adolescents with bipolar mania from 33.8 at baseline to 21.7 at month 1.

Phase 2 data demonstrates the effectiveness of LB-102, developed with the potential to be the first-in-class benzamide antipsychotic, for adults with acute schizophrenia.

This Month in Review captures 7 sleep medicine news, including FDA updates, from December 2024.

A study found intimate partner violence significantly lowers women's psychosocial well-being across finances, health, and relationships, but not men's.